Here’s Why You Should Be Buying Pfizer Like Its Insiders
Aug 25, 2020
Wall Street deal maker Ronald E. Blaylock has just made his first investment in Pfizer stock three years after he joined the board — signalling there is about to be an upward move in the company’s fortunes.
The Corporate Governance insider, who sits on the Audit Committee, snapped up $500k shares just three weeks ago ahead of the hotly anticipated Q4 $195bn Mylan and Upjohn mega-merger-Spinoff called Viatris — as well as the Cerevel Therapeutics Nasdaq IPO.